A Study of Letrozole in the Treatment of Endometrial Cancer
Phase 2
Completed
- Conditions
- Recurrent and Metastatic Endometrial Cancer
- Registration Number
- NCT00333086
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Response rates (complete response, partial response, no change, progressive disease) measured by tumor marker assessments and radiologic imaging at week 12 then every 12 weeks x 1 year followed by every 16 weeks
- Secondary Outcome Measures
Name Time Method Duration of clinical response, time to progression of the disease, correlation of tumor response with pretreatment ER/PR status, histological grade and aromatase levels
Trial Locations
- Locations (1)
Novartis Investigative Site
🇩🇪Heidelberg, Germany